Lightstone Ventures
Signal active
Investment Firm
Overview
Lightstone Ventures is a global venture capital firm that invests in personalized medicines and targeted therapeutics. Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing in breakthrough life science companies during a time of unique opportunity in space.
Highlights
Founded
2012
Industry
Financial Services
Employees
11-50
Investment
66
Lead Investment
18
Exits
12
Stages
Early Stage Venture, Late Stage Venture, Seed, Private Equity
Investor Type
Venture Capital
Location
United States, North America
Contact Information
Social
Profile Resume
Lightstone Ventures, established in 2012 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Seed, Private Equity investments across Biotechnology, Health Care, Medical, Biopharma, Venture Capital, Life Science, Medical Device, Finance, Payments, Financial Services. The organization boasts a portfolio of 66 investments, with an average round size of $52.7M and 12 successful exits. Their recent investments include Astria Therapeutics, SV Health Investors, Advanced Technology Ventures, MedImmune Ventures, Clarus Ventures. The highest investment round they participated in was $367.9B. Among their most notable exits are Astria Therapeutics and SV Health Investors. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Lightstone Ventures has made 66 investments. Their most recent investment was on Jun 10, 2024, when Amber Therapeutics raised $101.7M.
Lightstone Ventures has made 10 diversity investments. Their most recent diversity investment was on Aug 18, 2021, when Vigil Neuroscience raised $90.0M.
investments
66
Diversity investments
10
Lead investments
18
Number of exits
12
Investments
66
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Sep 06, 2023 | Nimbus Therapeutics | Biotechnology | 210.0M |
| Feb 20, 2024 | - | - | 42.0M |
| Apr 25, 2024 | Cerevance | Biotechnology | 47.0M |
| Jun 10, 2024 | Amber Therapeutics | Biotechnology | 101.7M |
Exits
12
Funding Timeline
Funding rounds
66
Investors
0
Funds
4
Funding Rounds
66
Lightstone Ventures has raised 66 rounds. Their latest funding was raised on Jun 10, 2024 from a Series A - Amber Therapeutics round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Sep 06, 2023 | Private Equity Round - Nimbus Therapeutics | - | 210.0M | - |
| Feb 20, 2024 | Series A - Reprieve Cardiovascular | - | 42.0M | - |
| Apr 25, 2024 | Series B - Cerevance | - | 47.0M | - |
| Jun 10, 2024 | Series A - Amber Therapeutics | - | 101.7M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.